文献速递复苏、休克与脓毒症儿科与产科急症重症综合管理与镇静镇痛

免疫功能低下儿童严重脓毒症与脓毒性休克的死亡风险

Risk of Mortality in Immunocompromised Children With Severe Sepsis and Septic Shock.
PubMed 文献 · Crit Care Med · 2020-01-01
一句话结论在严重脓毒症或脓毒性休克患儿中,28%存在免疫功能低下诊断;先天性免疫缺陷、多次既往恶性肿瘤、噬血细胞性淋巴组织细胞增生症及造血细胞移植与PICU死亡风险独立相关。

该回顾性多中心队列研究基于Virtual Pediatric Systems数据库83个中心,纳入2012年1月1日至2016年12月31日期间PICU收治的10,768例严重脓毒症或脓毒性休克患儿,其中3,021例(28%)存在免疫功能低下诊断。采用混合效应logistic回归模型分析发现,在未接受造血细胞移植的患儿中,先天性免疫缺陷(aOR 1.90,95%CI 1.24-2.92)、多次既往恶性肿瘤(aOR 1.86,95%CI 1.15-2.99)和噬血细胞性淋巴组织细胞增生症(aOR 3.09,95%CI 1.91-4.98)与PICU死亡风险增加相关。在既往接受造血细胞移植的患儿中,液体肿瘤(aOR 3.15,95%CI 2.09-4.74)、先天性免疫缺陷(aOR 6.94,95%CI 3.84-12.53)、多次既往恶性肿瘤(aOR 3.54,95%CI 1.80-6.95)和噬血细胞性淋巴组织细胞增生症(aOR 2.79,95%CI 1.36-5.71)与PICU死亡风险增加相关。PICU死亡率在不同中心间存在显著差异,中心每月脓毒症患者平均数量较高与PICU死亡率较低相关(aOR 0.94,95%CI 0.90-0.98)。免疫功能低下患儿的PICU资源利用因诊断和移植史而异,幸存者中免疫功能低下患者的中位PICU住院时间短于无免疫功能低下诊断者(p<0.001

要点

  • 在严重脓毒症或脓毒性休克的PICU患儿中,28%(3,021/10,768)存在免疫功能低下诊断。
  • 未接受造血细胞移植的患儿中,先天性免疫缺陷(aOR 1.90)、多次既往恶性肿瘤(aOR 1.86)和噬血细胞性淋巴组织细胞增生症(aOR 3.09)与PICU死亡风险增加独立相关。
  • 既往接受造血细胞移植的患儿中,液体肿瘤(aOR 3.15)、先天性免疫缺陷(aOR 6.94)、多次既往恶性肿瘤(aOR 3.54)和噬血细胞性淋巴组织细胞增生症(aOR 2.79)与PICU死亡风险增加独立相关。
  • PICU死亡率在不同中心间存在显著差异,中心每月脓毒症患者平均数量较高与PICU死亡率较低相关(aOR 0.94,95%CI 0.90-0.98)。
  • 幸存者中,免疫功能低下患者的中位PICU住院时间短于无免疫功能低下诊断者(p<0.001)。

适用人群与场景

  • 2012年1月1日至2016年12月31日期间入住参与中心PICU的严重脓毒症或脓毒性休克患儿。
  • 通过国际疾病分类第九版临床修订版(ICD-9-CM)编码识别严重脓毒症或脓毒性休克。

研究设计与关键结果

  • 研究类型:回顾性多中心队列研究,83个中心,纳入10,768例PICU严重脓毒症或脓毒性休克患儿,其中3,021例(28%)存在免疫功能低下诊断。
  • 未接受造血细胞移植患儿:先天性免疫缺陷aOR 1.90(95%CI 1.24-2.92)、多次既往恶性肿瘤aOR 1.86(95%CI 1.15-2.99)、噬血细胞性淋巴组织细胞增生症aOR 3.09(95%CI 1.91-4.98)与PICU死亡风险增加相关。
  • 既往接受造血细胞移植患儿:液体肿瘤aOR 3.15(95%CI 2.09-4.74)、先天性免疫缺陷aOR 6.94(95%CI 3.84-12.53)、多次既往恶性肿瘤aOR 3.54(95%CI 1.80-6.95)、噬血细胞性淋巴组织细胞增生症aOR 2.79(95%CI 1.36-5.71)与PICU死亡风险增加相关。
  • 中心每月脓毒症患者平均数量较高与PICU死亡率较低相关(aOR 0.94,95%CI 0.90-0.98)。
  • 幸存者中免疫功能低下患者的中位PICU住院时间短于无免疫功能低下诊断者(p<0.001)。

证据类型、等级与局限

  • 证据类型:回顾性多中心队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对PICU严重脓毒症或脓毒性休克患儿应识别免疫功能低下诊断,因其与PICU死亡风险增加独立相关。
  • 先天性免疫缺陷、多次既往恶性肿瘤、噬血细胞性淋巴组织细胞增生症及造血细胞移植史可作为风险分层参考。
  • 中心脓毒症收治量与PICU死亡率相关,提示中心因素可能影响结局。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: To assess the prevalence of immunocompromised diagnoses among children with severe sepsis and septic shock, and to determine the association between immunocompromised diagnoses and clinical outcomes after adjustment for demographics and illness severity.

DESIGN: Retrospective multicenter cohort study.

SETTING: Eighty-three centers in the Virtual Pediatric Systems database.

PATIENTS: Children with severe sepsis or septic shock admitted to a participating PICU between January 1, 2012, and December 31, 2016.

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: Across 83 centers, we identified 10,768 PICU admissions with an International Classification of Diseases, 9th Revision, Clinical Modification code for severe sepsis or septic shock; 3,021 of these patients (28%) had an immunocompromised diagnosis. To evaluate variation across centers and determine factors associated with PICU mortality, we used mixed-effect logistic regression models. Among patients without hematopoietic cell transplant, congenital immunodeficiency (adjusted odds ratio, 1.90; 95% CI, 1.24-2.92), multiple prior malignancies (adjusted odds ratio, 1.86; 95% CI, 1.15-2.99), and hemophagocytic lymphohistiocytosis (adjusted odds ratio, 3.09; 95% CI, 1.91-4.98) were associated with an increased odds of PICU mortality. Among patients with prior hematopoietic cell transplant, liquid malignancy (adjusted odds ratio, 3.15; 95% CI, 2.09-4.74), congenital immunodeficiency (adjusted odds ratio, 6.94; 95% CI, 3.84-12.53), multiple prior malignancies (adjusted odds ratio, 3.54; 95% CI, 1.80-6.95), and hemophagocytic lymphohistiocytosis (adjusted odds ratio, 2.79; 95% CI, 1.36-5.71) were associated with an increased odds of PICU mortality. PICU mortality varied significantly by center, and a higher mean number of sepsis patients per month in a center was associated with lower PICU mortality (adjusted odds ratio, 0.94; 95% CI, 0.90-0.98). PICU resource utilization varied by immunocompromised diagnosis and history of hematopoietic cell transplant, and among survivors immunocompromised patients have shorter median PICU length of stay compared with patients without immunocompromised diagnoses (p < 0.001).

CONCLUSIONS: Immunocompromised diagnoses are present in 28% of children with severe sepsis or septic shock. Multiple prior malignancies, hemophagocytic lymphohistiocytosis, congenital immunodeficiency, and hematopoietic cell transplant are independently associated with an increased odds of PICU mortality in children with severe sepsis or septic shock. Significant variation exists in PICU mortality among centers despite adjustment for immunocompromised diagnoses, known risk factors for sepsis-related mortality, and center-level sepsis volume.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Lindell RB, Nishisaki A, Weiss SL, et al. Risk of Mortality in Immunocompromised Children With Severe Sepsis and Septic Shock. Crit Care Med. 2020. PMID: 32301846. doi:10.1097/CCM.0000000000004329

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。